Nations Financial Group Inc. IA ADV Boosts Stake in Eli Lilly and Company (NYSE:LLY)

Nations Financial Group Inc. IA ADV raised its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 206.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,122 shares of the company's stock after buying an additional 4,124 shares during the quarter. Nations Financial Group Inc. IA ADV's holdings in Eli Lilly and Company were worth $4,763,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. Norges Bank bought a new stake in Eli Lilly and Company during the fourth quarter worth about $5,992,890,000. International Assets Investment Management LLC lifted its stake in Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company's stock worth $42,802,530,000 after purchasing an additional 7,330,815 shares during the last quarter. Sapient Capital LLC bought a new stake in Eli Lilly and Company during the fourth quarter worth about $682,139,000. J.P. Morgan Private Wealth Advisors LLC bought a new stake in Eli Lilly and Company during the third quarter worth about $435,736,000. Finally, Vanguard Group Inc. lifted its stake in Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company's stock worth $37,908,273,000 after purchasing an additional 659,838 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 2.8 %

Shares of NYSE:LLY traded down $20.94 during trading on Friday, hitting $734.97. The stock had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. The company has a market capitalization of $698.52 billion, a PE ratio of 108.24, a PEG ratio of 1.50 and a beta of 0.37. The company has a quick ratio of 0.73, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The firm's fifty day moving average is $761.06 and its 200 day moving average is $671.38. Eli Lilly and Company has a 12 month low of $419.80 and a 12 month high of $800.78.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period in the previous year, the company posted $1.62 earnings per share. The firm's revenue was up 26.0% on a year-over-year basis. Analysts anticipate that Eli Lilly and Company will post 13.83 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Citigroup lifted their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a "buy" rating in a research note on Tuesday, April 2nd. Bank of America boosted their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a "buy" rating in a research note on Friday, March 1st. Truist Financial boosted their target price on Eli Lilly and Company from $850.00 to $892.00 and gave the company a "buy" rating in a research note on Wednesday. Morgan Stanley boosted their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the company an "overweight" rating in a research note on Friday, February 16th. Finally, JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the company an "overweight" rating in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $757.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.